These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Letter: Digoxin tablets: a possible problem with biological availability. Am Heart J; 1973 Nov; 86(5):715. PubMed ID: 4800276 [No Abstract] [Full Text] [Related]
4. Editorial: What the practicing physician should know about digoxin bioavailability and how will FDA action affect him? Circulation; 1974 Mar; 49(3):399-400. PubMed ID: 4813171 [No Abstract] [Full Text] [Related]
5. Proceedings: The line-up on bioavailability. Schneller GH Rev Can Biol; 1973; 32():Suppl:151-5. PubMed ID: 4777598 [No Abstract] [Full Text] [Related]
6. APhA house of delegates endorses policies on pharmaceutical care, therapeutic outcomes, compounding, packaging. Am J Hosp Pharm; 1992 Jun; 49(6):1318. PubMed ID: 1529970 [No Abstract] [Full Text] [Related]
7. Bioavailability of digoxin. Vitti TG; Banes D; Byers TE N Engl J Med; 1971 Dec; 285(25):1433-4. PubMed ID: 5121213 [No Abstract] [Full Text] [Related]
8. Recognition of variable bioavailability as an international problem: a review of the earlier studies. Munro-Faure AD; Fowle AS; Fox J; Johnson BF; Lader S Postgrad Med J; 1974 Nov; 50 Suppl 6():14-8. PubMed ID: 4459882 [No Abstract] [Full Text] [Related]
9. [Bioavailability of digoxin tablets in Israel]. Levy M; Adler R; Superstein E; Eliakim M Harefuah; 1975 Aug; 89(4):153-4. PubMed ID: 1158280 [No Abstract] [Full Text] [Related]
11. The literature on formulation: its effect on drug product selection. Heller WM Am J Pharm Sci Support Public Health; 1977; 149(4):113-8. PubMed ID: 416721 [No Abstract] [Full Text] [Related]